Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us
EpiCast Report Acromegaly and Gigantism Epidemiology Forecast to 2023
Summary
Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH). GH excess beginning in adulthood is known as acromegaly, whereas GH excess beginning during childhood is known as gigantism.
To Browse a Full Report with Toc: http://www.researchmoz.us/epicast-report-acromegaly-and-gigantism-epidemiology-forecast-to-2023-report.html
GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of acromegaly in the 6MM from 25,354 diagnosed prevalent cases in 2013 to 26,884 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 0.60% in the forecast period. Similarly, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of gigantism in the 6MM from 591 diagnosed prevalent cases in 2013 to 621 diagnosed prevalent cases in 2023, at an AGR of 0.51% in the forecast period. The 6MM had an estimated 22,408 diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment in 2013, and the number of diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment is expected to increase to 23,765 by 2023, at an AGR of 0.61%.
GlobalData epidemiologists utilized comprehensive, country-specific data from national acromegaly registers and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of acromegaly, as well as the diagnosed prevalent cases of gigantism. For all the 6MM, acromegaly and gigantism cases were segmented by age and sex, and then further segmented into the type of pituitary adenoma, and the need for surgical intervention. Additionally, the cases of acromegaly and gigantism used in this forecast fulfilled the most commonly used diagnostic criteria across the globe, which are based on GH and IGF-1 levels. Finally, the same forecast methodology was used across the 6MM, thereby allowing for meaningful global comparisons of the diagnosed prevalent cases of acromegaly, and the diagnosed prevalent cases of gigantism across these markets.
Scope
- The Acromegaly and Gigantism EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for acromegaly and gigantism in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acromegaly and gigantism, segmented by sex, age (in 15-year age groups beginning at 15 years and ending at
lent Cases of Acromegaly and Gigantism with Macroadenomas 43
3.7.2 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Microadenomas 44
3.7.3 Diagnosed Prevalent Cases of Acromegaly and Gigantism Receiving Any Surgical Treatment 45
3.8 Discussion 46
3.8.1 Epidemiological Forecast Insight 46
3.8.2 Limitations of the Analysis 47
3.8.3 Strengths of the Analysis 47
4 Appendix 49
4.1 Bibliography 49
4.2 About the Authors 53
4.2.1 Epidemiologists 53
4.2.2 Reviewers 53
4.2.3 Acting Director of Epidemiology 54
4.2.4 Global Head of Healthcare 55
4.3 About GlobalData 56
4.4 About EpiCast 56
4.5 Disclaimer 57
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Acromegaly and Gigantism 11
Table 2: Summary of the Global Reported Cases and Estimated Prevalence of Acromegaly 13
Table 3: Global Consensus Criteria for the Diagnosis and Cure of Acromegaly 14
Table 4: Sources of Acromegaly and Gigantism Prevalence Data in the 6MM 14
Table 5: Sources of Macroadenoma, Microadenoma, and Surgery Data in the 6MM 15
Table 6: 6MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages
To Browse a Full Report with Toc: http://www.researchmoz.us/epicast-report-acromegaly-and-gigantism-epidemiology-forecast-to-2023-report.html
All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact US:
For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463
EpiCast Report Acromegaly and Gigantism Epidemiology Forecast to 2023
Summary
Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH). GH excess beginning in adulthood is known as acromegaly, whereas GH excess beginning during childhood is known as gigantism.
To Browse a Full Report with Toc: http://www.researchmoz.us/epicast-report-acromegaly-and-gigantism-epidemiology-forecast-to-2023-report.html
GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of acromegaly in the 6MM from 25,354 diagnosed prevalent cases in 2013 to 26,884 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 0.60% in the forecast period. Similarly, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of gigantism in the 6MM from 591 diagnosed prevalent cases in 2013 to 621 diagnosed prevalent cases in 2023, at an AGR of 0.51% in the forecast period. The 6MM had an estimated 22,408 diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment in 2013, and the number of diagnosed prevalent cases of acromegaly and gigantism receiving any surgical treatment is expected to increase to 23,765 by 2023, at an AGR of 0.61%.
GlobalData epidemiologists utilized comprehensive, country-specific data from national acromegaly registers and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of acromegaly, as well as the diagnosed prevalent cases of gigantism. For all the 6MM, acromegaly and gigantism cases were segmented by age and sex, and then further segmented into the type of pituitary adenoma, and the need for surgical intervention. Additionally, the cases of acromegaly and gigantism used in this forecast fulfilled the most commonly used diagnostic criteria across the globe, which are based on GH and IGF-1 levels. Finally, the same forecast methodology was used across the 6MM, thereby allowing for meaningful global comparisons of the diagnosed prevalent cases of acromegaly, and the diagnosed prevalent cases of gigantism across these markets.
Scope
- The Acromegaly and Gigantism EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for acromegaly and gigantism in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acromegaly and gigantism, segmented by sex, age (in 15-year age groups beginning at 15 years and ending at
lent Cases of Acromegaly and Gigantism with Macroadenomas 43
3.7.2 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Microadenomas 44
3.7.3 Diagnosed Prevalent Cases of Acromegaly and Gigantism Receiving Any Surgical Treatment 45
3.8 Discussion 46
3.8.1 Epidemiological Forecast Insight 46
3.8.2 Limitations of the Analysis 47
3.8.3 Strengths of the Analysis 47
4 Appendix 49
4.1 Bibliography 49
4.2 About the Authors 53
4.2.1 Epidemiologists 53
4.2.2 Reviewers 53
4.2.3 Acting Director of Epidemiology 54
4.2.4 Global Head of Healthcare 55
4.3 About GlobalData 56
4.4 About EpiCast 56
4.5 Disclaimer 57
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Acromegaly and Gigantism 11
Table 2: Summary of the Global Reported Cases and Estimated Prevalence of Acromegaly 13
Table 3: Global Consensus Criteria for the Diagnosis and Cure of Acromegaly 14
Table 4: Sources of Acromegaly and Gigantism Prevalence Data in the 6MM 14
Table 5: Sources of Macroadenoma, Microadenoma, and Surgery Data in the 6MM 15
Table 6: 6MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages
To Browse a Full Report with Toc: http://www.researchmoz.us/epicast-report-acromegaly-and-gigantism-epidemiology-forecast-to-2023-report.html
All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact US:
For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463
No comments:
Post a Comment